Exploring Different Effects of Exclusive Enteral Nutrition (EEN) and Corticosteroids on the Gut Microbiome in Crohn’s Disease Based on a Three-Stage Strategy

Dong Guo,1 Liang Fang,2 Ruiqing Liu,1 Yu Li,1 Liang Lv,1 Zhaojiao Niu,1 Dong Chen,1 Yanbing Zhou,1 and Weiming Zhu3

1Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, China
2Department of Gastroenterology, The affiliated hospital of Qingdao University, Qingdao, Shandong, China
3Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, China

Correspondence should be addressed to Weiming Zhu; njweimingzhu@126.com

Received 19 February 2022; Revised 2 July 2022; Accepted 4 July 2022; Published 27 July 2022

Academic Editor: Andrew Day

The objective of this study was to compare the efficacy of exclusive enteral nutrition (EEN) and corticosteroids on the gut microbiome in Crohn’s disease. Methods. Data were collected for 16 patients newly diagnosed with CD as the test group and 10 healthy volunteers as the control group. The 16 patients were randomly divided into the EEN group and the corticosteroids group. For subsequent analysis, 6 patients in the EEN group with follow-up were enrolled to compare the 0-month, 1-month, and 3-month outcomes. We analyzed and compared gut microbiota between different groups in 3 stages. To evaluate the clinical outcome of treatment, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin (HB), albumin (ALB), and Crohn’s disease activity (CDAI) were recorded. Results. There are significant differences in microbiota between patients with CD and healthy people, and there are intuitive differences in the main components of the microbiota. 16 patients were included in stage 2, in which both corticosteroids and EEN can induce CD remission well. However, corticosteroids have a greater impact on inflammatory indicators, while EEN has a more obvious effect on nutritional indicators. Principal component analysis suggests that there are different compositional changes in the gut microbiome after corticosteroids and EEN treatment. After 3 months of dynamic observation, we found that EEN can effectively maintain CD remission, reduce inflammatory indicators, and improve nutritional indicators. Conclusions. Both EEN and corticosteroids can increase the diversity of the microbiome in inducing CD remission, while they have different effects on the proportion of microbiome species. This trial is registered with NCT02056418.

1. Introduction

Crohn’s disease (CD) is a transmural, chronic, nonspecific inflammatory disorder affecting the entire digestive tract. In recent years, the incidence of CD is increasing in China, which could increase the morbidity associated with the disease in patients with CD. Some research ascribed the development of CD to the interaction of patients’ genetics factors, epigenetic factors, and microbial exposure [1–4]. However, the specific etiology of CD is still not clear.

EEN is usually regarded as a first-line treatment for CD, which could lead to a higher rate of mucosal healing. Compared with corticosteroid treatment, EEN could avoid some short-term and long-term side effects. Moreover, EEN could increase the likelihood of absorption and the following growth.

Therefore, in this study, we compared the outcome of induction therapy with exclusive enteral nutrition (EEN) to that of corticosteroids and to further compare the gut microbial composition between the two induction therapy strategies.
The microbial composition plays an important role in the pathogenesis of CD. Recent research showed in children’s CD, EEN can affect the microbiota while inducing remission [4]. There is still a lot of controversy about what changed after EEN treatment [5]. Corticosteroids are still the main intervention commonly used to induce the remission of active CD, of which long-term use will bring a lot of side effects. Generally speaking, they cannot improve the prognosis of CD and cannot promote mucosal healing [2]. In a recent study, they compared mucosal healing and bacterial composition in response to enteral nutrition with steroid-based induction therapy. They found both steroid and EEN-induced clinical remission. However, it demonstrated patients with EEN-induced remission showed a higher rate of mucosal healing and this was associated with a different gut microbiota compositional shift in these children [6].

In this study, we took a three-stage strategy: compared patients with CD with healthy people, compared EEN with corticosteroids treatment, and compared the follow-up in different times. The study compared the effect of 2 treatments on patients with CD and has a cohort of healthy controls to compare against, in which patients on EEN were sampled longitudinally. The results indicate that both corticosteroids and EEN have a good effect of inducing remission. Corticosteroids have a significant effect on improving inflammation indicators, while EEN has a relatively significant improvement on nutritional indicators. Both treatment methods have a tendency to increase the diversity of the intestinal tract, yet completely different effects on the species and composition of the microbiota or on specific bacterial species. Corticosteroids have a greater impact on the microbiota. Our study demonstrated that the process of EEN-induced CD remission can change the proportion of microbiota, increase the diversity of the microbiota, and make it tend to be more similar to that seen in healthy individuals with therapy. This may be the mechanism of EEN-induced CD remission and further experiments are needed.

2. Material and Methods

2.1. Study Workflow. To better understand the effects of exclusive enteral nutrition (EEN) in patients with Crohn’s disease and to compare with the effects of corticosteroids, we took a three-stage strategy: Patients with CD versus health volunteers, EEN treatment versus corticosteroids, and inner comparison 0, 1, and 3 months after EEN treatment (Figure 1).

2.2. Patients Selection and Exclusion Criteria. This study was approved by the Medical Ethics Committee of Nanjing General Hospital of Nanjing Military Command. From August 2013 to September 2014, inpatient volunteers were treated at the General Surgery Inflammatory Bowel Disease Center of Nanjing General Hospital of Nanjing Military Command. Patients need to meet all the selection criteria (satisfy all the selection criteria and not violate any exclusion criteria).

Patients that were 18–75 years old with CD, diagnosed through histopathology from endoscopic tissue biopsies, serum bloodwork (C-reactive protein (CRP) ≥10 mg/L), abdominal CT, and magnetic resonance enterography, were approached for recruitment. Patients were excluded if they were older than 75 years or younger than 18 years old, ever received any treatment. Patients were also excluded if they were in a very severe condition, including CDAI> =450, patients with extraintestinal fistula, abdominal abscess, or short bowel syndrome, and patients with other severe liver, kidney, cardiopulmonary, and nervous system diseases and immune-related diseases.

The healthy controls were subjects of 18-75 years old, without systemic diseases, without drinking and smoking history, and without a recent medication history.

2.3. Intervention. Patients in the EEN group were given enteral nutrition to induce remission. The specific scheme was as follows: the selected patients were given a nasal feeding tube and total enteral nutrition for 4 weeks. In the course of treatment, people can drink water, forbid other meals, forbid other drugs, and, if necessary, take phenopenidine orally to treat diarrhea. Heat card refers to indirect energy measurement results or 25-30 kcal/kg/d. Patients were hospitalized for treatment according to their condition or received family enteral nutrition treatment under the guidance of doctors. During the treatment, doctors and nurses should closely observe, control the infusion speed, adjust the temperature, prevent aspiration, and try to reduce patients’ enteral nutrition intolerance and complications. If the patient has enteral nutrition intolerance or complications, it should be adjusted in time according to the specific situation and treated symptomatically. If the patient does not tolerate the nasal feeding tube, adjust and replace the nasal feeding tube in time, or change to oral-nasal feeding alternately.

The patients in the steroid group were orally or intravenously administered with a dose equivalent to 0.75–1 mg • kg⁻¹ • d⁻¹ prednisone. After symptom relief, 5 mg was reduced every week, and when it was reduced to 20 mg/d, 2.5 mg was reduced every week until it was stopped. During the treatment, the patient ate normally and was forbidden to take other drugs. Pay attention to drug-related adverse reactions and handle them accordingly. Calcium and vitamin D should be supplemented at the same time. After adjusting the symptomatic treatment, if the hormone is intolerant, or the complications are not controlled, or the induction fails and the condition intensifies, the treatment plan shall be changed in time.

2.4. 16S rRNA Gene Sequencing. In order to get the gut microbiota diversity, we collected fecal samples of the participants for 16S rRNA gene sequencing. At the time of baseline collection, patients have not been treated yet. Within 3 days after enrollment, fecal samples were collected. The workflow of sample collection is as follows. In a clean environment, subjects were asked to use sterile cups to collect fecal samples. The experimenter collected fecal samples at multiple points in the super clean workbench, sub package to liquid nitrogen cryopreservation tube (2 parts, 2 ml each). After numbering, place it in liquid nitrogen for quick freezing. The above operations shall not
exceed 30 minutes. After overnight, it shall be placed in the -80°C deep low-temperature refrigerator for storage. After samples collection, fresh samples were stored at -80°C refrigerators or in liquid nitrogen tanks within 6 hours. The genomic DNA of bacteria was extracted from samples with the freeze–thaw method. The 16S rDNA was PCR-amplified and then sequenced on the MiSeq PE250 system (Illumina, USA). The primer sequence was F: 5′GTGCCAGCMGCCGCGGTAA3′ and R:5′GGACTACHVGGGTWTCTAAT3′.

2.5. Operational Taxonomic Unit (OTU) Clustering. OTU and abundance analysis includes preliminary OTU statistics, Venn diagram analysis, and PCA, which can provide a preliminary understanding of the species abundance and main component composition of the samples. The analysis of species and their abundance can obtain the species composition ratio of each sample at each taxonomic level (phyla, class, order, family, genera, and species), reflecting the community structure of the sample at different taxonomic levels. The detailed OTU count of each sample was provided in the supplementary table (available here).

2.6. Statistical Analysis. Continuous variables were expressed in the form of mean ± SD or mean ± SE. A t test/nonparametric test was used for comparison between groups. p < 0.05 is a statistically significant difference. The difference in the abundance of microbial communities was analyzed and the FDR (false discovery rate) was used to evaluate the significance of the difference. We used SPSS 18.0 and GraphPad Prism 5 for statistical analysis and graphing. For bioinformatics analysis, Qiime 1.7.0 was used to cluster sequencing data to form OTU, and annotate according to the database to make a dilution curve. Use R software to make Venn diagram and principal component analysis diagram. Combining the database Qiime to generate species abundance tables and multisample species distribution maps at different taxonomic levels (phyla, class, order, family, genera, and species). The specific values used the metastats command in the software mothur and the R software (rank-sum test, Fisher’s exact test, chi-square test, t test, square difference test) Perform significant difference analysis between groups, and the p-value correction method was “BH” method.

Table 1: Baseline characteristics of the study population.

|                | Corticosteroids | EEN |
|----------------|-----------------|-----|
| N              | 8               | 8   |
| Age at diagnosis | 29.3            | 30.8|
| Males          | 4               | 5   |
| Disease location |                |     |
| Ileal (L1)     | 2               | 1   |
| Colonic (L2)   | 2               | 2   |
| Ileocolonic (L3) | 4            | 5   |
| Disease behavior |              |     |
| B1             | 3               | 2   |
| B2             | 5               | 6   |
| History of corticosteroids | 3 | 1   |
| CDAI           | 274.81          | 253.86|

Abbreviations: EEN: exclusive enteral nutrition; CDAI: Crohn’s disease activity index.
3. Results

A total of 20 patients were involved in the study. After signing the informed consent form, patients with CD were randomly divided into a corticosteroid group and an enteral nutrition group (10 patients in each group). They received corticosteroid therapy and EEN, respectively, to induce remission. Among them, 4 patients were excluded (ever were under treatment before), and a total of 16 patients completed the study (Table 1).

3.1. Clinical Outcome. In stage 2, Table 2 shows that after 4 weeks of corticosteroids therapy, CDAI decreased significantly, and the inflammatory indicators CRP and ESR also decreased significantly after induction. Nutritional indicators that include HB (hemoglobin), ALB (albumin), body weight, and SM (skeletal muscle) were significantly improved, and the quality of HB was significantly improved before and after (102.45 ± 14.23 vs. 117.50 ± 10.85, p = 0.032). After 4 weeks of EEN treatment, CDAI decreased significantly, and inflammatory indicators (CRP and ESR) were also significantly improved. Nutritional indicators improved; HB and ALB were significantly improved (108.87 ± 12.85 vs 128.36 ± 9.91 p = 0.004; 30.86 ± 3.05 vs. 37.94 ± 3.40 p = 0.001); body weight and SM increased, but not statistically significant (Table 2). Due to the small number of research subjects, the induction effect cannot be evaluated. We found that corticosteroids have a greater impact on inflammation indicators, while EEN has a more obvious effect on nutritional indicators. It is worth pointing out that EEN is significantly better than corticosteroids therapy after induction. The patient’s serum albumin level was significantly higher than that of corticosteroid therapy (37.94 ± 3.40 vs. 33.19 ± 2.36, p = 0.006). All in all, corticosteroids and EEN have good clinical effects on the research population.

| Subject | Before (n=8) | After (n=8) | p value |
|---------|-------------|-------------|---------|
| CDAI    | 274.81 ± 92.14 | 98.63 ± 28.05 | <0.001 |
| ES (mm/h) | 37.70 ± 3.23 | 18.69 ± 3.88 | <0.001 |
| CRP (mg/L) | 35.79 ± 15.89 | 12.49 ± 3.80 | 0.001 |
| Corticosteroids (n=8) | | | |
| HB (g/L) | 102.45 ± 14.23 | 117.50 ± 10.85 | 0.032 |
| ALB (mg/L) | 31.00 ± 4.38 | 33.19 ± 2.36 | 0.234 |
| W (kg) | 47.23 ± 10.21 | 48.14 ± 10.99 | 0.866 |
| SMM (kg) | 21.68 ± 6.07 | 22.00 ± 6.19 | 0.920 |
| CDAI | 253.86 ± 71.69 | 103.71 ± 44.13 | <0.001 |
| ESR (mm/h) | 35.94 ± 12.25 | 19.0 ± 4.69 | 0.003 |
| CRP (mg/L) | 33.55 ± 14.28 | 13.88 ± 5.96 | 0.003 |
| EEN (n=8) | | | |
| HB (g/L) | 108.87 ± 12.85 | 128.36 ± 9.91 | 0.004 |
| ALB (mg/L) | 30.86 ± 3.05 | 37.94 ± 3.40 | 0.001 |
| W (kg) | 47.81 ± 8.23 | 49.19 ± 7.69 | 0.735 |
| SMM (kg) | 21.63 ± 5.61 | 23.01 ± 5.07 | 0.618 |

Abbreviations: CDAI: Crohn’s disease activity index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HB: hemoglobin; ALB: albumin; SM: skeletal muscle; before: before treatment; after: after treatment; W: weight.

Table 2: Clinical outcome of corticosteroids and EEN therapy.

In stage 3, Table 3 shows that patients who have completed the 3-month follow-up have achieved good clinical results when EEN maintains remission, and their clinical symptoms are well controlled. CDAI indicates disease remission, and there is a downward trend. Nutritional indicators, including albumin, body weight, and skeletal muscle, steadily increase during the maintenance of remission of EEN. The results suggest that when EEN maintains CD remission, it can well control disease activity and effectively maintain disease remission, reduce inflammation indicators, and improve nutritional status.

3.2. PCA. Through PCA, we intuitively observed the changes in the composition of the microbiota in different stages. On the two-dimensional coordinate graph, its coordinate axis takes two characteristic values that can reflect the maximum

| Subject | ENN0 (n=6) | ENN1 (n=6) | ENN3 (n=6) |
|---------|------------|------------|------------|
| CDAI    | 95.62 ± 18.39 | 94.83 ± 20.26 | 85.25 ± 16.32 |
| ESR (mm/h) | 17.67 ± 3.50 | 16.50 ± 3.27 | 16.83 ± 2.93 |
| CRP (mg/L) | 12.17 ± 3.19 | 9.67 ± 3.83 | 7.92 ± 3.01 |
| HB (g/L) | 128.07 ± 10.14 | 129.33 ± 12.88 | 132.42 ± 10.36 |
| ALB (mg/L) | 39.25 ± 2.52 | 39.33 ± 2.42 | 41.50 ± 2.26 |
| W (kg) | 46.75 ± 6.80 | 47.42 ± 6.34 | 49.08 ± 5.51 |
| SMM (kg) | 21.47 ± 4.67 | 21.73 ± 4.44 | 22.78 ± 4.33 |

Abbreviations: CDAI: Crohn’s disease activity index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HB: hemoglobin; ALB: albumin; SM: skeletal muscle; W: weight.

Table 3: Clinical outcome of EEN therapy in 0-month, 1-month, and 3-month follow-up.
In stage 1, the health group and CD group have an intersection of 594 OUT (Figure 3). The health group has a smaller abundance (890 vs. 783). The health group shows that compared with the health group, the CD group has a significantly higher abundance (75.5 vs. 382.3, p < 0.05). The green dot represents the sample after EEN treatment (ENPO), and the red represents the sample after EEN treatment (ENPO). It can be observed that the two groups are separated in the direction of PC2, indicating that the microbiota is different after corticosteroids and EEN treatment changes in composition.

In stage 3, red, blue and green, respectively, represent samples before corticosteroids treatment (GCPR) and before EEN treatment (ENPR). There is no significant trend of aggregation and separation between samples, and the distribution is even (p > 0.05). The green dot represents the sample after corticosteroids treatment (GCPO), and the red represents the sample after EEN treatment (ENPO). It can be observed that the two groups are separated in the direction of PC2, indicating that the microbiota is different after corticosteroids and EEN treatment changes in composition.

In stage 1, the health group and CD group are obviously distinct, indicating that the microbiota is different in composition between the two groups (Figure 2).

In stage 2, purple and blue, respectively, represent samples before corticosteroids treatment (GCPR) and before EEN treatment (ENPR). There is no significant trend of aggregation and separation between samples, and the distribution is even (p > 0.05). The green dot represents the sample after corticosteroids treatment (GCPO), and the red represents the sample after EEN treatment (ENPO). It can be observed that the two groups are separated in the direction of PC2, indicating that the microbiota is different after corticosteroids and EEN treatment changes in composition.

In stage 3, we want to make clear the long-term effect of EEN treatment on patients with CD.

In the EEN group, after 3-month follow-up, 121 OTU disappeared and 112 new OTU added, which are more than 1-month follow-up.

3.4. Taxonomic Abundance Analysis. A total of 12 phyla were measured, among which we selected the main phyla (relative abundance of the two groups > 1%), observed, and compared the effects of different groups on the microbiota (Figure 4).

In stage 1, the CD group, the abundance of Lentisphaerae, Synergistetes, and Chloroflexi was extremely low or even not detected. Compared with the healthy control group, the CD group had a significant increase in fecal Proteobacteria (16.3 ± 3.90 vs. 3.53 ± 0.99, p = 0.007, FDR = 0.0216); and Cyanobacteria (0.14 ± 0.01 × 10-2) vs. 0.38 ± 0.20, p = 0.009, FDR = 0.0221), Bacteroidetes (22.04 ± 6.48 vs. 50.3 ± 5.73, p = 0.01, FDR = 0.0276), and Tenericutes (0.10 ± 0.10 × 10-3 vs. 2.50 ± 1.08 × 10-2, p = 0.001, FDR = 0.043) significantly reduced.

In stage 2, the abundance of Actinobacteria and Bacteroidetes decreased after EEN treatment, but increased after corticosteroids treatment (p < 0.05). The abundance of Firmicutes and Fusobacteria showed an upward trend after EEN and corticosteroids treatment (p < 0.05). The abundance of Proteobacteria and Verrucomicrobia increased after EEN treatment but decreased after corticosteroids treatment (p < 0.05). These findings suggest that after EEN and corticosteroids induce CD remission, both have a profound impact on the microbiota, but they are microbiota-specific.

In stage 3, Synergistetes appeared after EEN maintained remission for 3 months; Tenericutes and Cyanobacteria gradually became undetectable during EEN treatment. When selecting the main phyla (relative abundance > 1%), and continuously observing the influence of EEN on the

![Figure 2: PCA in three stage. Abbreviations: HC: health control; CD: Crohn’s Disease; GCPR: before corticosteroids treatment; ENPR: before EEN treatment; GCPO: after corticosteroids treatment; ENPO: after EEN treatment; EN0: 0 month after EEN treatment; EN1: 1 month after EEN treatment; EN3: 3 months after EEN treatment.](image-url)
abundance of specific microbiota, there is no statistical difference in its changes, but there is a clear trend. The relative abundance of Fusobacteria and Proteobacteria in EEN maintained a rising trend during the remission process, while the relative abundance of Verrucomicrobia and Actinobacteria showed a downward trend. Bacteroidetes and Firmicutes maintained remission in EEN with different trends. The relative abundance of Bacteroidetes in EEN maintained remission for 1 month showed an increasing trend and continued to maintain treatment for 2 months, its abundance shows a downward trend, while Firmicutes is just the opposite.

4. Discussion

The pathogenesis of CD is not clear, which is related to multiple factors such as genetics, environment, and microbiota. Among them, the interaction between the microbiota and the occurrence and development of CD has become one of the main hotspots in exploring the pathogenesis of CD [7–9]. From clinical studies that described the microbiota and clinical manifestations to genetic studies based on the interaction between susceptibility genes and symbiotic bacteria, it has been confirmed that CD is closely related to microbiota [10, 11]. In the treatment of CD, EEN has received more attention. In addition to its ability to induce and maintain CD remission, EEN has the advantages of promoting mucosal healing, improving nutritional status, regulating mucosal microbiota, and improving quality of life. Meanwhile, it is favored by clinicians that many areas have become the first choice for the treatment of CD, especially children’s CD [12–17]. At present, there is still no definite theory to explain how EEN induces CD remission. Scholars elucidate the mechanism from maintaining the intestinal mucosal barrier, regulating the microbiota, inducing mucosal healing, regulating microRNA, and reducing mesenteric fat [3, 4]. Studies have confirmed that the EEN treatment process can have an impact on the microbiota, including the proportion of the main microbiota, the "key" bacteria

![Figure 3: The number of OTU in different groups. Abbreviations: HC: health control; CD: Crohn’s Disease; GCPR: before corticosteroids treatment; ENPR: before EEN treatment; GCPO: after corticosteroids treatment; ENPO: after EEN treatment; EN0: 0 month after EEN treatment; EN1: 1 month after EEN treatment; EN3: 3 months after EEN treatment.](image-url)
and the diversity of the microbiota [5]. At present, the research on EEN treatment and microbiota has not reached a conclusive conclusion. There is a similar study on the role of EEN in ulcerative colitis (UC), in which they demonstrated that the gut microbiota of pediatric UC and patients of EEN in ulcerative colitis (UC), in which they demonstrated that it has an increasing trend after EEN treatment and decreases after corticosteroids treatment. The increase of CD Escherichia coli, especially the increase of mucoadhesive Escherichia coli, will promote intestinal inflammation and aggravate intestinal mucosal damage [20]. The abundance of EEN increased after induction of remission but decreased significantly after corticosteroids induction. The results prove that the composition of the microbiota is complex and interacts closely with the host. EEN and corticosteroids, as two different induction methods, have an impact on the composition of the intestinal bacteria. In the process of EEN and corticosteroids-induced CD remission, the diversity of the microbiota has an increasing trend. The effect of corticosteroids is greater, but there is no statistical difference. After EEN-induced remission, the components of Fusobacteria and Proteobacteria increased, and the Actinomycota gradually decreased, showing a trend toward healthy people.

### 5. Conclusion

In conclusion, there are significant differences in microbiota between patients with CD and healthy people. Preliminary OTU statistical analysis shows that compared with EEN, corticosteroids therapy has a greater effect on the microbiota. Principal component analysis suggests that there are different compositional changes in the microbiota after hormone and EEN treatment. Both corticosteroids and EEN have a good effect of inducing remission.
After 3 months of dynamic observation, we found that EEN can effectively maintain CD remission, reduce inflammatory indicators, and improve nutritional indicators. Maintaining CD remission has less impact on the microbiota, which could increase the diversity of microbiota. The analysis showed that patients became more similar to healthy controls after the EEN treatment. This may be one of the mechanisms by which EEN induces and maintains CD remission.

Our work proved that both EEN and corticosteroids can increase the diversity of the microbiome in inducing CD remission, while they have different effects on the proportion of microbiome species. However, our work is at the macroscopic level and more experiments need to be conducted to explore the function of a specific microbiome species.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Supplementary Materials
A full OTU count table was provided in the supplementary table. (Supplementary Materials)

References
[1] J. Torres, S. Mehandrur, J. F. Colombel, and L. Peyrin-Biroulet, “Crohn’s disease,” The Lancet, vol. 389, no. 10080, pp. 1741–1755, 2017.
[2] B. Veauthier and J. R. Hornecker, “Crohn’s disease: diagnosis and management,” American family physician, vol. 98, no. 11, pp. 661–669, 2018.
[3] J. Mazal and C. Truluck, “Organizing and leading a journal club,” Radiologic technology, vol. 85, no. 5, pp. 549–553, 2014.
[4] A. MacLellan, J. Connors, S. Grant, L. Cahill, M. Langille, and J. van Limbergen, “The impact of exclusive enteral nutrition (EEN) on the gut microbiome in Crohn’s disease: a review,” Nutrients, vol. 9, no. 5, p. 0447, 2017.
[5] J. J. Ashton, J. Gavin, and R. M. Beattie, “Exclusive enteral nutrition in Crohn’s disease: evidence and practicalities,” Clinical nutrition, vol. 38, no. 1, pp. 80–89, 2019.
[6] V. Svolos, R. Hansen, B. Nichols et al., “Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition,” Gastroenterology, vol. 156, no. 5, pp. 1354–1367.e6, 2019.
[7] S. Coward, M. E. Kuenzig, G. Hazlewood et al., “Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network metaanalysis,” Inflammatory bowel diseases, vol. 23, no. 3, pp. 461–472, 2017.
[8] J. Du, L. Fu, Y. Sui, and L. Zhang, “The function and regulation of OTU deubiquitinases,” Frontiers of Medicine, vol. 14, no. 5, pp. 542–563, 2020.
[9] A. R. Weingarden and B. A.-O. Vaughn, “Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease,” Gut microbes, vol. 8, no. 3, pp. 238–252, 2017.
[10] A. Szwidsinska, A. Ladhoff, A. Pernthaler et al., “Mucosal flora in inflammatory bowel disease,” Gastroenterology, vol. 122, no. 1, pp. 44–54, 2002.
[11] R. Ungaro, C. N. Bernstein, R. Gearry et al., “Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis,” The American journal of gastroenterology, vol. 109, no. 11, pp. 1728–1738, 2014.
[12] O. Borrelli, L. Cordischi, M. Cirulli et al., “Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial,” Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, vol. 4, no. 6, pp. 744–753, 2006.
[13] A. Andoh, T. Tsujikawa, M. Sasaki et al., “Faecal microbiota profile of Crohn’s disease determined by terminal restriction fragment length polymorphism analysis,” Alimentary pharmacology & therapeutics, vol. 29, no. 1, pp. 75–82, 2009.
[14] A. S. Day, K. E. Whitten, D. A. Lemberg et al., “Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach,” Journal of gastroenterology and Hepatology, vol. 21, no. 10, pp. 1609–1614, 2006.
[15] A. D. Levin, V. Wadhera, S. T. Leach et al., “Vitamin D deficiency in children with inflammatory bowel disease,” Digestive diseases and sciences, vol. 56, no. 3, pp. 830–836, 2011.
[16] N. A. Afzal, H. J. Van der Zaag, F. Arnaud-Battandier et al., “Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition,” Alimentary pharmacology & therapeutics, vol. 20, no. 2, pp. 167–172, 2004.
[17] Z. Guo, R. Wu, W. Zhu et al., “Effect of exclusive enteral nutrition on health-related quality of life for adults with active Crohn’s disease,” Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition, vol. 28, no. 4, pp. 499–505, 2013.
[18] H. M. Martin, B. J. Campbell, C. A. Hart et al., “Enhanced _Escherichia coli_ adherence and invasion in Crohn’s disease: a randomized controlled open-label trial,” Gastroenterology, vol. 127, no. 1, pp. 80–93, 2004.
[19] K. Dobashi, D. B. Weiner, and M. I. Greene, “Differsitional regulation of oncogenic and cellular p185 by serine/threonine kinases,” DNA, vol. 8, no. 10, pp. 723–732, 1989.
[20] N. Rolhion and A. Darfeuille-Michaud, “Adherent-invasive _Escherichia coli_ in inflammatory bowel disease,” Inflammatory bowel diseases, vol. 13, no. 10, pp. 1277–1283, 2007.